Liraglutide to Retatrutide Dose Conversion Guide

How Liraglutide and Retatrutide Work Differently

Understanding why a simple dose conversion table does not exist starts with understanding what each drug actually does inside the body.

Liraglutide is a GLP-1 receptor agonist. It works by mimicking glucagon-like peptide-1, a hormone that slows gastric emptying, reduces appetite, and supports insulin release. It is taken as a daily injection and is approved under the brand names Victoza for type 2 diabetes and Saxenda for weight management.

Retatrutide takes a broader approach. It targets three receptors simultaneously: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple agonist activity creates a wider metabolic effect, influencing energy expenditure, fat metabolism, and appetite through multiple pathways at once. Retatrutide is administered weekly, which also reflects its longer duration of action compared to liraglutide.

Because these drugs work through different mechanisms with different receptor profiles and dosing schedules, switching between them is a pharmacological step-up, not a straight substitution.

Why a Direct Mg-to-Mg Conversion Does Not Exist

Patients and even some clinicians may expect a conversion chart similar to what exists for opioids or thyroid medications. For liraglutide to retatrutide, that chart simply does not exist, and it cannot be reliably constructed from current evidence.

No head-to-head pharmacokinetic bridging studies have established a formal conversion ratio between these two medications. The drugs differ in half-life, with liraglutide requiring daily dosing and retatrutide dosed weekly. They differ in receptor targets, as described above. They also differ in potency profiles across those targets.

The pivotal phase 2 retatrutide data, published in the New England Journal of Medicine in 2023, used a fixed titration protocol starting at 2 mg weekly for all participants, regardless of prior GLP-1 experience. That design reflects the clinical reality: there is no validated shortcut for GLP-1-experienced patients. Everyone begins at the starting line.

Comparing the Two Medications at a Glance

The table below summarizes the key practical differences between liraglutide and retatrutide to help patients and caregivers prepare for a prescriber conversation.

The Typical Titration Protocol When Switching

For most patients moving from liraglutide to retatrutide, the standard approach mirrors what was used in the phase 2 clinical trials. That means starting at 2 mg of retatrutide weekly for four weeks, then stepping up to 4 mg, then 8 mg, and potentially reaching 12 mg based on individual tolerability.

Because liraglutide has a relatively short half-life of roughly 13 hours, a formal pharmacological washout period is not required before starting retatrutide. However, some prescribers prefer a brief gap of one to three days to allow any residual GI effects from liraglutide to settle before introducing a new agent. This decision should be individualized.

The key principle is that prior GLP-1 experience does not justify skipping titration steps. The glucagon receptor component of retatrutide adds an entirely new layer of gut and metabolic activity that the body needs time to adjust to, even in someone who tolerated liraglutide at full dose without difficulty.

Managing Side Effects During the Transition

GI symptoms are the most commonly reported concern when switching to retatrutide. Nausea, vomiting, and diarrhea are possible during dose escalation, and the triple agonist mechanism means they may feel different or more intense compared to what a patient experienced on liraglutide.

Glucagon receptor activation can add to the gut motility effects already associated with GLP-1 therapy. This combination may temporarily produce stronger nausea than liraglutide users are accustomed to, even at the starting dose.

First-line strategies for managing GI effects include eating smaller, lower-fat meals, staying well hydrated, and paying attention to dose timing. If symptoms are difficult to manage, a prescriber may consider slowing the titration pace rather than discontinuing retatrutide entirely. Patients should not adjust their dose schedule without clinician guidance.

Heart rate changes are also worth monitoring. Retatrutide's glucagon component has cardiac activity that differs from pure GLP-1 therapy, making baseline cardiovascular history an important part of the pre-switch conversation.

What to Discuss With Your Prescriber Before Making the Switch

Before initiating any transition, several practical and clinical questions deserve attention.

First, confirm current availability. As of early 2025, retatrutide had not received FDA approval. Access outside of clinical trials may be limited to compounding pharmacies in specific circumstances, and those situations carry their own regulatory and quality considerations. Checking on the current approval status at the time of your consultation is essential.

Second, review your cardiovascular history in light of the glucagon agonism component. The cardiac considerations for a triple agonist differ from those for a pure GLP-1 medication, and patients with existing heart conditions may need additional monitoring or evaluation.

Third, establish a structured monitoring plan. During titration, checking weight, blood glucose or A1C, heart rate, and GI tolerance at four-week intervals provides the data needed to make safe dose escalation decisions. The glucagon receptor component can have a modest glucose-raising effect that is generally offset by enhanced GLP-1 and GIP activity, but A1C monitoring after the switch helps confirm that balance is maintained.

Doctronic's first AI legally authorized to practice medicine offers free consultations so patients can organize their questions and arrive at a prescriber appointment fully prepared, without the time and cost barriers that often delay these conversations.

Frequently Asked Questions

Can I switch from liraglutide to retatrutide without a washout period?

A washout period is not pharmacologically required because liraglutide has a short half-life of roughly 13 hours. However, some prescribers prefer a 1 to 3 day gap before starting retatrutide. Talk with your clinician about the timeline that makes the most sense for your individual health situation.

What is the starting dose of retatrutide for someone already on a GLP-1 medication?

Even for GLP-1-experienced patients, the recommended starting dose used in phase 2 trials was 2 mg weekly. Clinicians generally do not skip titration steps because retatrutide's added glucagon receptor activity can produce new GI effects that require a gradual adjustment period to manage safely.

Is retatrutide more effective than liraglutide for weight loss?

Phase 2 trial data published in NEJM 2023 showed retatrutide at 12 mg produced up to 24% body weight reduction at 48 weeks. Liraglutide averages 8 to 10% in trials. Patients switching due to inadequate weight loss on liraglutide are the most likely candidates to see meaningful additional benefit with retatrutide.

Will I experience more nausea switching from liraglutide to retatrutide?

It is possible. Glucagon receptor activation adds to GLP-1-mediated gut motility effects, which may temporarily worsen nausea, vomiting, or diarrhea. Patients who tolerated liraglutide well should not assume the same tolerance carries over. Low-fat meals, adequate hydration, and careful dose timing are first-line strategies.

Is retatrutide FDA approved and how do I get access to it?

As of early 2025, retatrutide had not received FDA approval. Access may be possible through ongoing clinical trials or, in limited circumstances, compounding pharmacies. Confirm current availability and eligibility with a licensed prescriber before pursuing any access pathway, as the regulatory status may have changed.

The Bottom Line

Switching from liraglutide to retatrutide is not a plug-and-play conversion. The two medications work through fundamentally different receptor pathways, and no validated mg-to-mg conversion ratio exists. Retatrutide's triple agonist profile offers substantially greater weight loss potential, but it also introduces new side effect considerations that require careful, individualized titration starting at the lowest available dose. Doctronic offers free AI consultations and $39 video visits available 24/7, so patients can prepare thoroughly for this conversation with a prescriber on their own schedule and budget. With 99.2% treatment plan alignment with board-certified physicians, Doctronic can help you organize your questions and understand your options before making any medication change. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.